Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Non-Small Cell Lung Cancer (ASCO) Basic Listing

Updates in Non-Small Cell Lung Cancer
From the ASCO Annual Meeting

Suresh Ramalingam, MD
Conference Coverage
06/02/2024
Suresh Ramalingam, MD
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed...
06/02/2024
Oncology
Paul Paik, MD, Memorial Sloan Kettering Cancer Center
Videos
07/17/2023

Featuring Paul Paik, MD

Featuring Paul Paik, MD
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Ticiana Leal, MD, Winship Cancer Institute
Videos
07/17/2023

Featuring Ticiana Leal, MD 

Featuring Ticiana Leal, MD 
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...
At the 2023 ASCO Annual Meeting,...
07/17/2023
Oncology
Roy Herbst, MD, PhD, Yale Cancer Center
Videos
06/19/2023
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
06/19/2023
Oncology
06/19/2023

Stephanie Holland

Stephanie Holland
Results from the phase 2 WU-KONG6 study demonstrate superior antitumor efficacy with sunvozertinib in pretreated patients with NSCLC and EGFR exon20 insertion mutations when compared to current available therapies.
Results from the phase 2 WU-KONG6 study demonstrate superior antitumor efficacy with sunvozertinib in pretreated patients with NSCLC and EGFR exon20 insertion mutations when compared to current available therapies.
Results from the phase 2...
06/19/2023
Oncology
Conference Coverage
06/09/2023

Stephanie Holland

Stephanie Holland
Findings from the phase 1b TROPION-Lung02 study presented at the 2023 ASCO Annual Meeting, demonstrate tolerable safety and notable first-line activity with datopotamab deruxtecan plus pembrolizumab among patients with NSCLC.
Findings from the phase 1b TROPION-Lung02 study presented at the 2023 ASCO Annual Meeting, demonstrate tolerable safety and notable first-line activity with datopotamab deruxtecan plus pembrolizumab among patients with NSCLC.
Findings from the phase 1b...
06/09/2023
Oncology
Conference Coverage
06/09/2023

Amber Denham

Amber Denham
According to phase 1/2 data presented at the 2023 ASCO Annual Meeting, BLU-945, as a monotherapy and in combination with osimertinib, was generally well tolerated and showed strong on-target EGFR ctDNA reduction.
According to phase 1/2 data presented at the 2023 ASCO Annual Meeting, BLU-945, as a monotherapy and in combination with osimertinib, was generally well tolerated and showed strong on-target EGFR ctDNA reduction.
According to phase 1/2 data...
06/09/2023
Oncology
Anna Minchom, MD
Videos
06/04/2023
Anna Minchom, MBBCh, MRCP, MD(Res), discusses updated safety results from the PALOMA trial and the identified recommended phase 2 dose for subcutaneous biweekly administration of amivantamab for patients with advanced solid malignancies.
Anna Minchom, MBBCh, MRCP, MD(Res), discusses updated safety results from the PALOMA trial and the identified recommended phase 2 dose for subcutaneous biweekly administration of amivantamab for patients with advanced solid malignancies.
Anna Minchom, MBBCh, MRCP,...
06/04/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement